ABSTRACT
Importance Substance use disorders (SUDs) incur serious social and personal costs. Screening techniques that identify persons at risk before problems develop can improve prevention efforts.
Objective To examine whether models that include polygenic scores (PGS) and a clinical/ environmental/risk index (CERI) are able to identify individuals as having a lifetime SUD.
Design We tested the predictive power of PGS and CERI for lifetime diagnosis of DSM-IV substance dependence using four longitudinal cohorts.
Setting The study included four samples: 1) the National Longitudinal Study of Adolescent to Adult Health (Add Health); 2) the Avon Longitudinal Study of Parents and Children (ALSPAC); 3) the Collaborative Study on the Genetics of Alcoholism (COGA); and 4) the Finnish Twin Cohort Study (FinnTwin12) for a combined sample of N = 15,134.
Participants Participants in Add Health (NEUR = 4,855; NAFR = 1,605) and COGA (NEUR = 1,878; NAFR = 870) included individuals of both European and African ancestries. Participants in ALSPAC (NEUR = 4,733) and FinnTwin12 (NEUR = 1,193) were limited to individuals of European ancestries.
Exposures A clinical/environmental risk index (CERI) composed of ten items and PGS for phenotypes with strong genetic overlap with SUDs (drinks per week, problematic alcohol use, externalizing problems, major depressive disorder, and schizophrenia).
Main Outcomes Meeting lifetime criteria for DSM-IV: 1) alcohol dependence, 2) drug dependence, and 3) any substance dependence (alcohol, other drug, or nicotine).
Results In the models containing the five PGS and CERI, the CERI was associated with all three outcomes (ORs = 1.35 – 1.64). PGS for problematic alcohol use was associated with alcohol dependence (OR = 1.14), PGS for externalizing was associated with drug dependence (OR = 1.14) and both were associated with any substance dependence (ORs = 1.11 – 1.19). Including the five PGS, CERI, and covariates explained 6% - 13% of the variance in SUDs. Those in the top 10% of CERI and PGS had relative risk ratios of 3.82 - 9.13 for each SUD relative to the bottom 90%.
Conclusions and Relevance Measures of clinical, environmental, and genetic, risk demonstrate modest ability to distinguish between affected and unaffected individuals for alcohol, drug, and any substance use disorders in young adulthood. These tools will continue to advance as we identify additional risk factors that can be incorporated into clinical practice and deliver on the goal of precision medicine.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was was supported by the National Institute on Alcohol Abuse and Alcoholism and the National Institute of Drug Abuse of the National Institutes of Health under award numbers R01AA015416, R01DA050721, and K02AA018755; the Academy of Finland (grants 100499, 205585, 118555, 141054, 265240, 308248, 308698 and 312073); the Scientific and Technological Research Council of Turkey (TÜBİTAK) under award number 114C117 (FA); and the Sigrid Juselius Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of Virginia Commonwealth University waived ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data in the present study are available upon application and approval by the constituent cohorts.